Why Thermo Fisher Scientific Stock Tumbled Today

Core Viewpoint - Investors reacted negatively to Thermo Fisher Scientific's recent acquisitions, leading to a decline in its stock price, which fell more than 1% compared to the S&P 500's 0.7% drop [1] Group 1: Acquisition Details - Thermo Fisher completed two acquisitions, with the more significant one being the $4 billion purchase of Solventum's purification and filtration business, previously part of 3M [2] - The second acquisition involved a sterile finish-and-fill factory in New Jersey, previously owned by Sanofi, which will continue to manufacture therapies for Sanofi while expanding its capacity for other pharmaceutical and biotech customers [5][6] Group 2: Financial Impact - The new unit from the Solventum acquisition is expected to negatively impact Thermo Fisher's bottom line in the first year, reducing non-GAAP adjusted net income by $0.06 per share [4] - By the fifth year of ownership, the business is projected to generate approximately $125 million in adjusted operating income due to anticipated revenue and cost synergies [5]